We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Vernalis | LSE:VER | London | Ordinary Share | GB00B3Y5L754 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.17 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMVER
RNS Number : 2499A
Vernalis PLC
29 December 2017
TOTAL VOTING RIGHTS
VERNALIS PLC (the "Company")
29 December 2017
Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,819,624 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.
The total number of voting rights in the Company is therefore 526,819,624.
The above figure of 526,819,624 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company.
- ends -
Enquiries:
Vernalis plc: +44 (0) 118 938 0015 Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer Canaccord Genuity Limited (Nominated Adviser and Joint Broker): +44 (0) 20 7523 8000 Henry Fitzgerald-O'Connor Emma Gabriel Shore Capital (Joint Broker): +44 (0) 20 7408 4090 Mark Percy Toby Gibbs FTI Consulting: +44 (0) 20 3727 1000 Ben Atwell Simon Conway Stephanie Cuthbert Stern Investor Relations: +1 212 362 1200 Stephanie Ascher Jane Urheim
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra(R) XR, targeting the US prescription cough-cold market; Moxatag(R) , a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, and Tris.
For further information about Vernalis, please visit www.vernalis.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRUURURBKAUUAA
(END) Dow Jones Newswires
December 29, 2017 02:00 ET (07:00 GMT)
1 Year Vernalis Chart |
1 Month Vernalis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
